Idetrexed and Olaparib for ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests two drugs, idetrexed and olaparib, in people with a type of ovarian cancer that has stopped responding to standard treatments. It aims to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-grade serous ovarian cancer that hasn't responded to standard treatments or you've chosen not to have other treatments.
- Your cancer can be measured on scans or by blood tests.
- You are 18 years or older.
- Your overall health is good (able to do daily activities with little help).
- Your heart and lung function are within normal limits.
- If you could become pregnant, you must use two forms of birth control or be sexually abstinent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, DS-8201a and olaparib, for people with cancers that have a protein called HER2, and for those with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink or control the cancer.
This trial tests a combination of three drugs (olaparib, durvalumab, and bevacizumab) given before surgery for women with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if this treatment shrinks the cancer enough to allow successful surgery.
This trial tests a combination of two targeted drugs, EZH2 inhibitor and PARP inhibitor, for people with advanced or recurrent epithelial ovarian cancer that does not have BRCA1/2 gene mutations. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests a combination of three drugs (Ipalotinib, Sunitinib, and Olaparib) given before surgery to shrink tumors in people with a specific type of advanced ovarian cancer that has a genetic marker called HRD-positive. The goal is to see if this treatment helps make surgery more effective.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a PARP inhibitor (olaparib) for people whose ovarian cancer came back at least 6 months after finishing platinum-based chemo. The goal is to see if this approach is safe and works better than chemo alone.
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
Hear when a new High Grade Serous Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.